Profile data is unavailable for this security.
About the company
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
- Revenue in USD (TTM)978.00k
- Net income in USD-21.62m
- Incorporated2014
- Employees23.00
- LocationLongeveron Inc1951 NW 7th Ave, Ste 520MIAMI 33136United StatesUSA
- Phone+1 (305) 302-7158
- Fax+1 (302) 674-5266
- Websitehttps://www.longeveron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genprex Inc | 0.00 | -27.63m | 6.53m | 26.00 | -- | 0.6828 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.78m | 5.00 | -- | 0.5451 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 6.83m | 22.00 | -- | 0.3591 | -- | 0.5845 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.01k | -13.61m | 6.85m | 12.00 | -- | 0.7396 | -- | 456.72 | -0.8257 | -0.8257 | 0.0008 | 0.3515 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 6.90m | 22.00 | -- | 1.18 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Longeveron Inc | 978.00k | -21.62m | 6.98m | 23.00 | -- | 0.9109 | -- | 7.14 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Trevena Inc | 3.14m | -40.15m | 7.15m | 23.00 | -- | -- | -- | 2.28 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 7.20m | 0.00 | -- | -- | -- | 9.49 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 7.24m | 1.00 | -- | 0.6726 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 7.30m | 64.00 | -- | -- | -- | 0.2455 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 7.33m | 17.00 | -- | 0.6151 | -- | 2.59 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Healthy Extracts Inc | 2.56m | -2.76m | 7.38m | -- | -- | 48.67 | -- | 2.88 | -0.9512 | -0.9512 | 0.8819 | 0.0512 | 0.9428 | 0.5035 | 32.10 | -- | -101.47 | -53.78 | -375.65 | -146.65 | 68.46 | 45.68 | -107.63 | -87.53 | 0.1293 | -2.22 | 0.879 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 7.43m | 15.00 | -- | 0.3379 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 7.48m | 80.00 | -- | 0.7009 | -- | 0.1454 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| BioNexus Gene Lab Corp | 9.78m | -2.66m | 7.51m | 30.00 | -- | 0.8032 | -- | 0.7678 | -0.14 | -0.14 | 0.651 | 0.5289 | 1.01 | 8.55 | 5.80 | -- | -27.53 | -3.83 | -33.16 | -5.02 | 13.56 | 14.55 | -27.25 | -3.04 | 3.98 | -162.45 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
Data as of May 31 2024. Currency figures normalised to Longeveron Inc's reporting currency: US Dollar USD
1.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 24.13k | 0.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.06k | 0.33% |
| Creative Planning LLCas of 31 Mar 2024 | 10.93k | 0.33% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.60k | 0.08% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 463.00 | 0.01% |
| PNC Bank, NA (Investment Management)as of 31 Mar 2024 | 297.00 | 0.01% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 128.00 | 0.00% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 83.00 | 0.00% |
| LGT Financial Advisors LLCas of 31 Mar 2024 | 35.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 12.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
